Dupixent
The latest news about Dupixent: headlines, AI summaries and the full story from every source.
- Regeneron Reports Strong Q3 2026 Results Driven by Sanofi Collaboration and Libtayo Growth
- Regeneron's Future May Depend on Dupixent Amid Eylea Sales Decline
- UBS Resumes Buy Rating on Regeneron Amid Undervaluation of Dupixent Potential
- Regeneron Reports Strong Performance from EYLEA HD, Dupixent Growth, and Upcoming Pipeline Catalysts
- Regeneron Pharmaceuticals Reports Strong Q2 Growth Driven by Dupixent, EYLEA HD
- Sanofi Raises Full-Year Outlook Amid Strong Q2 Performance Driven by Dupixent Growth
- Regeneron Exceeds Quarterly Estimates, Driven by Strong Sales of Eczema Drug Dupixent
- Sanofi Exceeds Earnings and Revenue Estimates, Raises FY26 Outlook
- Regeneron Exceeds First-Quarter Earnings Estimates with Dupixent Growth